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Abstract
Background: Borderline personality disorder (BPD) is a complex clinical state with highly polymorphic symptoms
and signs. Studies have demonstrated that people with a BPD diagnosis are likely to have numerous co-occurring
psychiatric disorders and physical comorbidities. The aim of our study was to obtain further insight about the
associations among comorbidities of BPD and to demonstrate the practicality of using association rule mining
(ARM) technique in clinical databases.
Methods: A retrospective case–control study was conducted on information of 1460 patients (292 BPD patients
and 1168 control patients) selected from the Taiwan National Health Insurance Research Database. Information on
physical and psychiatric comorbidities, which were diagnosed within 3 years before and after enrollment, was
collected. A logistic regression model was used to calculate the odds ratios of comorbidities between patients with
and without BPD. ARM technique was used to study the associations of BPD and two or more psychiatric comorbidities.
Results: We classified physical comorbidities into 13 categories according to the International Classification of Diseases,
Ninth Revision, Clinical Modification system, and the results indicated that the 12 categories were more common in the
BPD patients than in the control patients (except congenital anomalies). However, psychiatric comorbidities, including
depressive disorder, bipolar disorder, anxiety disorder, sleep disorder, substance use disorder, and mental retardation
were more common in the BPD patients than in the control patients. Furthermore, the associations of BPD and two or
more comorbidities were evaluated.
Conclusion: Most physical and psychiatric disorders were more common in the BPD patients than in the control
patients. Because the failure to remit from BPD is associated with suffering from chronic physical conditions and because
psychiatric comorbidities may lead to delays in diagnosis of BPD, clinicians caring for people with BPD should be aware
of possible comorbidities.
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Background
Borderline personality disorder (BPD) is one of the most
prevalent mental disorders, and it accounts for approxi-
mately 2.7–5.9% of the world’s general population [1, 2],
with slightly higher rates among women, people younger
than 30 years of age, and people who are separated or
divorced [3]. This disorder constitutes 10% of mental
health clients observed in outpatient clinical settings and
15–20% of those in inpatient settings [4, 5]. BPD is a se-
vere and complex psychological disorder characterized
by pervasive instability in regulating emotions, self-image,
interpersonal relationships, and impulse control [6]. BPD
is associated with high psychosocial and socioeconomic
costs [7]. The economic burden of diseases associated
with BPD is higher than that of those associated with de-
pression and comparable to that of patients with schizo-
phrenia [8]. BPD is associated with severe functional
impairment, substantial treatment use, and high rates of
mortality by suicide [9–11]. For example, a study reported
that among people with high rates of inpatient psychiatric
hospitalization, 19% met the criteria for BPD based on
clinical record diagnosis [12]. In addition, patients with
BPD are frequently encountered in emergency depart-
ments, where they present following a suicide attempt or
threatened suicide. More than 500 000 such events occur
each year in the United States [13], and 10% of BPD pa-
tients die by suicide [14].
BPD is a complex clinical state with highly polymorphic
symptoms and signs. Studies have demonstrated that
people with a BPD diagnosis are likely to have numerous
co-occurring psychiatric disorders, such as mood disorder,
anxiety disorder, substance use disorder, and other person-
ality disorders [3, 15–19]. However, most of these comor-
bidity studies of BPD have been conducted according to
the prevalence of the co-occurrence of two diagnoses, and
an entire association among three or more comorbid dis-
eases remains under investigation. The association of co-
morbidities of a disorder is important but there are only
some studies focusing on this issue [20, 21]. In addition,
little empirical evidence has been found to demonstrate
the association between BPD and physical comorbidities.
Association rule mining (ARM) has been used in many
studies with clinical dataset [21–31]. In 2003, Chen [31]
first introduced an application of ARM to Taiwan Na-
tional Health Insurance Research Database (NHIRD) and
showed the co-prescription patterns for antacids among
enrollees. In 2009, Chiu [21] applied ARM to study the as-
sociation among two or more comorbid disease of atten-
tion deficit hyperactivity disorder (ADHD). Therefore, we
believe that it has potential practicality of using ARM
technique in NHIRD and ARM could be applied in study-
ing the comorbidities of BPD.
The aim of the present analysis was to explore the phys-
ical and psychiatric comorbidities of BPD by using the
NHIRD and the ARM technique. The odds ratios (ORs) of
comorbidities between patients with and without BPD were
also surveyed. Our objective was to obtain further insight
about the associations among comorbidities of BPD.
Methods
Data source
Taiwan instituted the National Health Insurance (NHI)
program, a mandatory single-payer program that offers
comprehensive medical care coverage, including outpatient,
inpatient, emergency, and traditional Chinese medicine
services, to almost 98% of residents on March 1, 1995
[32]. Moreover, as of 2014, 99.9% of Taiwan’s population
was enrolled and foreigners in Taiwan were also eligible
for the NHI program.
Since 1996, the NHI reimbursement data in Taiwan
have been transferred to the National Health Research
Institute (NHRI) for further management and organization.
In addition, as part of these efforts, the work of NHRI has
resulted in establishing a national health care database
called NHIRD, which contains comprehensive information
on clinical practices, including patients’ demographic
characteristics, medical expenditure, prescription claims
data, surgery code, treatment code, and diagnostic codes
based on the International Classification of Disease, Ninth
Revision, Clinical Modification (ICD-9-CM).
The use of NHIRD is limited to research purposes only.
Researchers must follow the Computer-Processed Personal
Data Protection Law (http://www.winklerpartners.com/?
p=987) and the regulations of NHRI. In addition, an agree-
ment must be signed by the researchers and their super-
visor upon application submission. All applications for the
databases release would be reviewed for approval by ex-
perts in NHIR. Furthermore, confidentiality is also main-
tained based on the directives of the Bureau of NHI. In the
current study, the Longitudinal Health Insurance Database
2005 (LHID 2005), which is a dataset released by the
NHRI, was used as the data source. The LHID 2005 con-
tains all the original claims data of 1,000,000 beneficiaries
enrolled in year 2005 randomly sampled from the year
2005 Registry for Beneficiaries of the NHIRD, where regis-
tration data of everyone who was a beneficiary of the NHI
program during the period of January 1st 2005 to January
1st, 2006. There are approximately 25.68 million individ-
uals in this registry. All the registration and claims data of
these 1,000,000 individuals collected by the NHI program
constitute the LHID 2005. The NHRI reported that no sig-
nificant difference exists in the average insured payroll-
related amount, sex distribution, or age distribution be-
tween patients in the LHID 2005 and those in the NHIRD.
Study population
The data extracted from the LHID 2005 were used to
conduct a retrospective case–control study on patients
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who were newly diagnosed with BPD (ICD-9-CM code:
301.83) by a psychiatrist between January 1, 2003 and
December 31, 2006. For each BPD patient, 4 age- and
sex-matched control patients without BPD were ran-
domly selected from the LHID 2005 between 2003 and
2006. The random assignment procedures were performed
by SAS statistical software and were based on the random
numbers which were generated from the uniform distribu-
tion. Information on physical and psychiatric comorbidi-
ties, which were diagnosed within 3 years before and after
enrollment, was collected. In this study, all comorbidities
were categorized according to the original classification of
the ICD-9-CM system. Details regarding psychiatric disor-
ders including depressive disorder, bipolar disorder, anxiety
disorder, substance use disorder (e.g., alcohol use disorder,
opioid use disorder, and amphetamine use disorder), sleep
disorder, eating disorder, autistic spectrum disorder, mental
retardation, and ADHD were categorized for the ARM
analysis.
Statistical analysis
The prevalence rate of comorbidities in the BPD and
control patients was calculated, and independent t and
chi-squared tests were used to examine the differences
in the demographic characteristics between the BPD and
control patients. A univariable logistic regression model
was also used to calculate the ORs of physical and psy-
chiatric comorbidities between the BPD and control pa-
tients. In addition, although the coverage rate of the
NHI system in Taiwan is up to 99%, there is still a very
low incidence of missing data in the dataset. However, in
our study, the missingness was unrelated to the variables,
as so called missing completely at random. Therefore, we
have adopted the most commonly complete case analyses
method to accomondate these missing data-to simply ex-
clude those participants in our dataset who have any data
missing. SAS statistical software for Windows, Version 9.3
(SAS Institute, Cary, NC, USA), was used for data extrac-
tion, computation, data linkage, processing, and sampling.
All other statistical analyses were conducted using SPSS
statistical software for Windows, Version 20 (IBM,
Armonk, NY, USA). Comparisons with P < .05 indicated
statistically significant relationships.
Association rule mining
ARM is one of the most useful methods for discovering
patterns or extracting co-occurrences from transactional
databases. Recently, ARM has been applied in clinical
data analysis [21, 33]. A collection of entire diagnoses
can be defined as a set of items, and enrollees’ clinical
records can be represented as transactions, which in-
clude their historical combination sets. Therefore, the
basic concept of ARM used in clinical data analysis can
be outlined as follows.
Let I be a complete set of diagnoses (i.e., items in con-
ventional ARM) and T = {T1, T2,…, Tm} be a set of enrol-
lees’ clinical records (i.e., transactions in conventional
ARM), where Ti (1 ≤ i ≤m) is a set of diagnoses for en-
rollee i (ie, Ti⊆ I). Given two nonoverlapping sets of
diagnoses, X and Y (X ⊂ I, Y ⊂ I and X∩Y = ϕ), an associ-
ation rule is an implication of the form X→ Y (which is
read as “X implies Y”), indicating that if a set of diagno-
ses X occurs, then a set of diagnoses Y also occurs in the
enrollee’s clinical record [34]. X and Y represent the
antecedent and consequent of the rule, respectively.
Two measures, support and confidence, must be assessed
in the mining process to discover association rules. The
rule X→ Y has support s in T if s% of the enrollees’ clinical
records in T contains X∪Y; the rule has confidence c if c%
of enrollees’ clinical records in T that support X also
support Y. The confidence c could be also expressed as
Probability (Y|X) [P (Y|X)]. Given a user-specified mini-
mum support (called minsup) and minimum confidence
(called minconf ), the goal of ARM is to discover all as-
sociation rules that have support and confidence greater
than minsup and minconf, respectively.
Although the support-confidence framework for ARM
has been widely studied in the literature [21, 33], it is a
challenging task to set minsup and minconf simultan-
eously in real world application [35, 36]. To address this
issue, we disregard minsup and minconf and consider only
the interestingness of rules in ARM. Previous studies indi-
cate that using interestingness measures can quickly
evaluate the quality of rules and thus facilitate the rule
consolidation process [37]. This study chooses the lift as
the interestingness measure. The lift of the rule X→ Y is
defined as follows:
lift X→Yð Þ ¼ c X→Yð Þ
s Yð Þ ¼
P Y Xjð Þ
P Yð Þ ¼
P X;Yð Þ
P Xð Þ  P Yð Þ
The value of lift means that how much does the joint
probability P (X, Y) deviate from the independence as-
sumption P (X) × P (Y). Based on the above equation, we








if X and Y are positively correlated
if X and Y are independent
if X and Y are negatively correlated
The objective of this study was to determine the main
psychiatric comorbidity of BPD by using ARM. In this
study, analyses of ARM were conducted using Weka 3.6
open-source machine learning software (www.cs.waikato.
ac.nz/ml/weka). The Apriori module in WEKA was used to
discover interesting association rules relating to comorbid-
ity of BPD. To apply the lift metric in Apriori module, we
set both minsup and minconf as 0% and specify the metric
type as lift. The minimum value of lift is defined as 1 in
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order to discover the rules having positive correlation be-
tween their antecedent and consequent.
Based on the above setting, all the interesting associ-
ation rules (ie, lift > 1) will be outputted in descending
order by their lift values in WEKA. Although the lift
metric can prune less meaningful rules during the min-
ing process, the number of generated rules is still huge
because of disregarding minsup and minconf thresholds.
In this study, we confine the number of generate rules in
WEKA. Specifically, we generate top-k (k = 10,000) inter-
esting rules by specifying parameter k in WEKA.
In order to evaluate whether the discovered associ-
ation rules hold in general, we partitioned the collected
data into training and testing sets. Specifically, two third
of patients were randomly selected as the training set to
discover association rules and the remaining one third of
patients (testing set) were used to validate the discovered
association rules [38, 39].
Because small supports were noted in some discovered
association rules, bootstrap simulation was also used to
validate the discovered association rules. Of the 292
BPD patients included in our study, a random sample of
292 BPD patients is drawn with replacement (Therefore,
this sample will include some BPD patients multiple
times, and other BPD patients will be excluded at ran-
dom.). The 292 BPD patients were matched to 4 controls
according to age and sex, resulting in a bootstrap sample.
The association rules on this bootstrap sample were
evaluated. Above steps were repeated 1000 times to
create 1000 bootstrap samples. The mean support, con-
fidence, lift, and ORs with 95% confidence interval (CI)
of 1000 bootstrap samples were calculated.
Results
Patient selection
Our study included 292 BPD patients and 1168 control
patients, 65% of whom were women. The median age at
enrollment was 25 years (interquartile range, 21–33 y).
Table 1 shows comparisons of demographic variables be-
tween the BPD and control patients.
Odds ratios of physical comorbidities between the
borderline personality disorder and control patients
The results of the univariable logistic regression analysis
(Table 2) indicated that the ORs for having 12 categories
of physical comorbidities, except congenital anomalies,
were greater for the BPD patients than for the control
patients, particularly for comorbidities resulting from in-
jury and poisoning (OR = 4.84, 95% CI = 3.45–6.78). In
addition, the ORs for having comorbidities of the respira-
tory system (OR = 4.09, 95% CI = 1.49–11.2); digestive
system (OR = 3.32, 95% CI = 1.33–8.31); genitourinary
system (OR= 14.7, 95% CI = 8.15–26.5); endocrine, meta-
bolic, and immune system (OR= 2.68, 95% CI = 1.43–5.01);
neoplasm (OR= 2.58, 95% CI = 1.33–5.01); and blood and
blood-forming system (OR = 4.08, 95% CI = 1.54–10.8)
were greater for female BPD patients than for male BPD
patients.
Odds ratios of psychiatric comorbidities between the
borderline personality disorder and control patients
The results of the univariable logistic regression analysis
(Table 3) showed that the ORs for having depressive dis-
order (OR = 220, 95% CI = 133–364), bipolar disorder
(OR = 261.1, 95% CI = 157–434), anxiety disorder (OR =
13.2, 95% CI = 9.53–18.4), substance use disorder (OR=
73.3, 95% CI = 24.2–253), sleep disorder (OR = 6.82, 95%
CI = 5.00–9.29), and mental retardation (OR = 6.11, 95%
CI = 2.43–15.3) were greater for BPD patients than for
control patients. In addition, the ORs for having depres-
sive disorder (OR = 2.16, 95% CI = 1.18–3.96), bipolar
disorder (OR = 2.34, 95% CI = 1.21–4.53), anxiety disorder
(OR = 1.87, 95% CI = 1.14–3.06), and sleep disorder
(OR = 1.85, 95% CI = 1.11–3.09) were greater for female
BPD patients than for male BPD patients, but the ORs for
having substance use disorder (OR = 0.49.8, 95% CI =
0.27–0.92) and mental retardation (OR = 0.10, 95% CI =
0.01–0.89) were lower for female BPD patients than for
male BPD patients.
Association rule mining for psychiatic comorbidities of
borderline personality disorder
Table 4 lists the results of ARM for psychiatric comorbidi-
ties in training set. Thirteen association rules reached the
selected thresholds. Those rules are as follows: BPD⇒
bipolar disorder and anxiety disorder (support: 8.5%,
confidence: 43%, lift: 4.41); BPD⇒ depressive disorder
and anxiety disorder (support: 8.2%, confidence: 41%,
lift: 4.39); BPD⇒ bipolar disorder and sleep disorder
(support: 7.3%, confidence: 36%, lift: 4.37); BPD⇒
depressive disorder and sleep disorder (support: 7.1%,
confidence: 35%, lift: 4.41); BPD⇒ anxiety disorder and
sleep disorder (support: 4.9%, confidence: 25%, lift: 3.37);
BPD ⇒ bipolar disorder, anxiety disorder, and sleep
disorder (support: 4.6%, confidence: 23%, lift: 4.49);
Table 1 Characteristics of patients with borderline personality
disorder (BPD) and comparison subjects
BPD, N = 292 (%) Control, N = 1168 (%) P values
Sex 0.999
Male 102 (34.9) 408 (34.9)
Female 190 (65.1) 760 (65.1)
Age (years)a 25 (21–33) 25 (21–33) 0.999
Distribution of age 0.999
0–19 37 (12.7) 148 (12.7)
20–39 226 (77.4) 904 (77.4)
40–59 29 (9.9) 116 (9.9)
aMedian (interquartile range)
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BPD ⇒ depressive disorder, anxiety disorder, and sleep
disorder (support: 4.4%, confidence: 22%, lift: 4.47);
BPD ⇒ bipolar disorder and substance use disorder
(support: 3.2%, confidence: 16%, lift: 4.99); BPD ⇒
depressive disorder and substance use disorder (support:
3.0%, confidence: 15%, lift: 4.99); BPD ⇒ depressive
disorder, anxiety disorder, and substance use disorder
(support: 1.6%, confidence: 8.2%, lift: 4.99); BPD ⇒
substance use disorder and sleep disorder (support:
1.5%, confidence: 7.7%, lift: 4.99); BPD ⇒ depressive
disorder, substance use disorder, and sleep disorder
(support: 1.4%, confidence: 7.4%, lift: 4.99); and BPD ⇒
bipolar disorder, substance use disorder, and sleep dis-
order (support: 1.4%, confidence: 7.2%, lift: 4.99).
Table 5 shows results of applying rules discovered in
training set to testing set Those results are as follows:
BPD⇒ bipolar disorder and anxiety disorder (support:
9.1%, confidence: 45%, lift: 4.80); BPD⇒ depressive dis-
order and anxiety disorder (support: 8.7%, confidence:
43%, lift: 4.90); BPD⇒ bipolar disorder and sleep
Table 2 Physical comorbidity rates of borderline personality disorder (BPD) cases and non-BPD controls with diseases categorized in
ICD-9-CM coding system
BPD BPD (total)c (%) Non-BPD (total)d (%) OR 95% CI
Category of comorbid
disease
ICD 9 CM codes Female (%) Male (%) ORa 95% CIb
Respiratory system 460–519 96.8 88.2 4.09 1.49–11.2e 93.8 88.2 2.04 1.23–3.39e
Nervous system and
sense organs
320–389 72.6 64.7 1.45 0.86–2.43 69.9 52.9 2.15 1.63–2.83e
Digestive system 520–579 95.8 87.3 3.32 1.33–8.31e 92.8 81.9 2.85 1.78–4.55e
Skin and subcutaneous
tissue
680–709 72.6 65.7 1.39 0.83–2.33 70.2 56.0 1.85 1.41–2.44e
Injury and poisoning 800–999 84.7 84.3 1.03 0.53–2.01 84.6 53.2 4.84 3.45–6.78e
Infectious and parasitic 001–139 52.1 42.2 1.49 0.92–2.43 48.6 35.6 1.71 1.32–2.22e
Genitourinary system 580–629 81.1 22.5 14.7 8.15–26.5e 60.6 46.3 1.78 1.37–2.31e
Musculoskeletal system 710–739 65.3 61.8 1.16 0.71–1.92 64.0 42.1 2.45 1.88–3.19e
Congenital anomalies 740–759 3.68 2.94 1.26 0.32–4.99 3.42 1.63 2.14 0.99–4.66
Endocrine, metabolic
and immunity
240–279 31.6 14.7 2.68 1.43–5.01e 25.7 14.3 2.07 1.52–2.82e
Neoplasm 140–239 27.4 12.7 2.58 1.33–5.01e 22.3 11.5 2.21 1.59–3.07e
Circulatory system 390–459 29.5 23.5 1.36 0.78–2.36 27.4 11.1 3.01 2.20–4.13e
Blood and blood-forming
organs
280–289 17.4 4.90 4.08 1.54–10.8e 13.0 4.79 2.97 1.93–4.59e
a OR odds ratio, b CI confidence interval, c Total BPD cases, d Total non-BPD controls, e Statistical significance
Table 3 The comorbid psychiatry diseases of borderline personality disorder (BPD) cases and non-BPD controls
BPD BPD (total)c (%) Non-BPD (total)d (%) OR 95% CI
Comorbid psychiatry diseases Female (%) Male (%) ORa 95% CIb
Depressive disorder 86.3 74.5 2.16 1.18–3.96e 82.2 2.05 220 133–364e
Bipolar disorder 89.5 78.4 2.34 1.21–4.53e 85.6 2.23 261 157–434e
Anxiety disorder 52.6 37.3 1.87 1.14–3.06e 47.3 6.34 13.2 9.53–18.4e
Sleep disorder 44.7 30.4 1.85 1.11–3.09e 39.7 8.82 6.82 5.00–9.29e
Substance use disorder 13.2 23.5 0.49 0.27–0.92e 16.8 0.26 73.3 24.2–253e
Alcohol use disorder 8.42 20.6 0.36 0.18–0.72e 12.7 0.26 56.3 17.2–184.1e
Opioid use disorder 2.11 1.96 1.08 0.19–5.97 2.05 0 − −
Amphetamine use disorder 3.16 0.98 3.29 0.39–27.7 2.40 0 − −
ADHD 1.05 2.94 0.35 0.06–2.14 1.71 0 − −
Mental retardation 0.53 4.9 0.10 0.01–0.89e 2.05 0.26 6.11 2.43–15.3e
Autistic spectrum disorder 0 0.53 − − 0.34 0 − −
Eating disorder 0 3.68 − − 2.40 0 − −
aOR odds ratio, bCI confidence interval, cTotal BPD cases, dTotal non-BPD controls, eStatistical significance
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disorder (support: 7.2%, confidence: 36%, lift: 4.75);
BPD⇒ depressive disorder and sleep disorder (support:
7.0%, confidence: 35%, lift: 4.88); BPD⇒ anxiety disorder
and sleep disorder (support: 5.4%, confidence: 27%, lift:
3.96); BPD⇒ bipolar disorder, anxiety disorder, and sleep
disorder (support: 4.9%, confidence: 25%, lift: 4.82);
BPD⇒ depressive disorder, anxiety disorder, and sleep
disorder (support: 4.7%, confidence: 24%, lift: 5.02);
BPD⇒ bipolar disorder and substance use disorder (sup-
port: 2.7%, confidence: 13%, lift: 5.02); BPD⇒ depressive
Table 4 Results of association rule mining of comorbid psychiatric disorders among Borderline personality disorder (BPD) cases in
training set
Relations Support (%) Confidence (%) Lift Rule BPDa Non-BPDb ORc 95% CId
3 8.5 43 4.41 BPD ➔ Bipolar disorder & Anxiety disorder 84 11 52.8 27.3–102e
3 8.2 41 4.39 BPD ➔ Depressive disorder & Anxiety disorder 80 11 48.5 25.1–93.9e
3 7.3 36 4.37 BPD ➔ Bipolar disorder & Sleep disorder 70 10 43.0 21.6–85.7e
3 7.1 35 4.41 BPD ➔ Depressive disorder & Sleep disorder 68 9 45.7 22.3–94.0e
3 4.9 25 3.37 BPD ➔ Anxiety disorder & Sleep disorder 49 23 11.0 6.51–18.6e
4 4.6 23 4.49 BPD ➔ Bipolar disorder & Anxiety disorder & Sleep
disorder
45 5 46.4 18.1–119e
4 4.4 22 4.47 BPD ➔ Depressive disorder & Anxiety disorder &
Sleep disorder
43 5 43.7 17.0–112e
3 3.2 16 4.99 BPD ➔ Bipolar disorder & Substance use disorder 31 0 − −
3 3.0 15 4.99 BPD ➔ Depressive disorder & Substance use disorder 29 0 − −
4 1.6 8.2 4.99 BPD ➔ Depressive disorder & Anxiety disorder &
Substance use disorder
16 0 − −
3 1.5 7.7 4.99 BPD ➔ Substance use disorder & Sleep disorder 15 0 − −
4 1.4 7.2 4.99 BPD ➔ Depressive disorder & Substance use disorder
& Sleep disorder
14 0 − −
4 1.4 7.2 4.99 BPD ➔ Bipolar disorder & Substance use disorder
& Sleep disorder
14 0 − −
aNumber of BPD patients having the comorbidities in the rule
bNumber of non-BPD patients having the comorbidities in the rule
cOR odds ratio; dCI confidence interval; eStatistical significance
Table 5 Results of applying rules discovered in training set to testing set
Relations Support (%) Confidence (%) Lift Rule BPDa Non-BPDb ORc 95% CId
3 9.1 45 4.80 BPD ➔ Bipolar disorder & Anxiety disorder 44 2 161 37.9–684e
3 8.7 43 4.90 BPD ➔ Depressive disorder & Anxiety disorder 42 1 297 40.1–2202e
3 7.2 36 4.75 BPD ➔ Bipolar disorder & Sleep disorder 35 2 109.5 25.7–467e
3 7.0 35 4.88 BPD ➔ Depressive disorder & Sleep disorder 34 7 29.5 12.5–69.5e
3 5.4 27 3.96 BPD ➔ Anxiety disorder & Sleep disorder 26 7 20.0 8.38–47.9e
4 4.9 25 4.82 BPD ➔ Bipolar disorder & Anxiety disorder &
Sleep disorder
24 1 128 17.0–960e
4 4.7 24 5.02 BPD ➔ Depressive disorder & Anxiety disorder
& Sleep disorder
23 0 − −
3 2.7 13 5.02 BPD ➔ Bipolar disorder & Substance use disorder 13 0 − −
3 2.7 13 5.02 BPD ➔ Depressive disorder & Substance use disorder 13 0 − −
4 1.0 5.2 5.02 BPD ➔ Depressive disorder & Anxiety disorder &
Substance use disorder
5 0 − −
3 2.1 10 5.02 BPD ➔ Substance use disorder & Sleep disorder 10 0 − −
4 2.1 10 5.02 BPD ➔ Depressive disorder & Substance use disorder
& Sleep disorder
10 0 − −
4 2.1 10 5.02 BPD ➔ Bipolar disorder & Substance use disorder &
Sleep disorder
10 0 − −
aNumber of BPD patients having the comorbidities in the rule
bNumber of non-BPD patients having the comorbidities in the rule
cOR odds ratio; dCI confidence interval; eStatistical significance
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disorder and substance use disorder (support: 2.7%, con-
fidence: 13%, lift: 5.02); BPD⇒ depressive disorder, anx-
iety disorder, and substance use disorder (support: 1.0%,
confidence: 5.2%, lift: 5.02); BPD⇒ substance use dis-
order and sleep disorder (support: 2.1%, confidence:
10%, lift: 5.02); BPD⇒ depressive disorder, substance use
disorder, and sleep disorder (support: 2.1%, confidence:
10%, lift: 5.02); and BPD⇒ bipolar disorder, substance
use disorder, and sleep disorder (support: 2.1%, confidence:
10%, lift: 5.02). The results of association rules including
support, confidence, and lift were similar in training set
and testing set.
Furthermore, the results of bootstrap simulation were
presented in Table 6 and the results revealed that the as-
sociation rules discovered in our study were statistically
significant.
Discussion
The key findings in our study are outlined as follows: (1)
The 12 categories of physical comorbidities classified ac-
cording to the ICD-9-CM system were more common in
the BPD patients than in the control patients (except
congenital anomalies); (2) the psychiatric comorbidities
including depressive disorder, bipolar disorder, anxiety
disorder, sleep disorder, substance use disorder, and men-
tal retardation were more common in the BPD patients
than in the control patients; (3) depressive disorder, bipo-
lar disorder, anxiety disorder, and sleep disorder were
more prevalent for female BPD patients than for male
BPD patients, but substance use disorder and mental re-
tardation were less prevalent for female BPD patients than
for male BPD patients; (4) the associations of BPD and
two or more comorbidities were demonstrated in our
work by using ARM.
In this study, we observed that the 12 categories of phys-
ical comorbidities classified according to the ICD-9-CM
system were more common in the BPD patients than in
the control patients. The results were consistent with those
of previous studies. A national study in the United States
showed that BPD was significantly associated with arterio-
sclerosis or hypertension, hepatic disease, cardiovascular
disease, gastrointestinal disease, arthritis, venereal disease,
and “any assessed medical condition” [40]. In addition,
McWilliams et al. demonstrated that BPD symptoms were
positively associated with chronic spinal pain, frequent
headaches, and other chronic pain conditions [41]. Because
the failure to remit from BPD seemed to be associated with
a heightened risk of suffering from chronic physical
Table 6 Mean support, confidence, lift, and odds ratio (ORs) of association rules of comorbid psychiatric disorders among Borderline
personality disorder (BPD) cases of 1000 bootstrap samples
Relations Support (%) 95% CIa Confidence (%) 95% CIa Lift 95% CIa Rule OR 95% CIa
3 8.69 8.65–8.73b 43.4 43.2–43.7b 4.39 4.38–4.40b BPD ➔ Bipolar disorder & Anxiety
disorder
53.0 52.1–53.9b
3 8.35 8.31–8.38b 41.7 41.6–41.9b 4.41 4.40–4.42b BPD ➔ Depressive disorder & Anxiety
disorder
53.7 52.8–54.62b
3 7.26 7.22–7.29b 36.3 36.1–36.5b 4.33 4.32–4.34b BPD ➔ Bipolar disorder & Sleep
disorder
42.8 42.0–43.6b
3 7.04 7.01–7.08b 35.2 35.1–35.1b 4.35 4.34–4.36b BPD ➔ Depressive disorder & Sleep
disorder
43.8 43.0–44.6b
3 5.07 5.04–5.10b 25.3 25.2–25.5b 3.56 3.55–3.58b BPD ➔ Anxiety disorder & Sleep
disorder
13.4 13.2–13.6b
4 4.73 4.69–4.76b 23.6 23.5–23.8b 4.40 4.39–4.41b BPD ➔ Bipolar disorder & Anxiety
disorder & Sleep disorder
42.4 41.2–43.6b
4 4.52 4.49–4.55b 22.6 22.4–22.7b 4.39 4.38–4.40b BPD ➔ Depressive disorder & Anxiety
disorder & Sleep disorder
41.8 40.7–43.0b
3 3.01 2.99–3.04b 15.1 14.9–15.2b 4.91 4.90–4.91b BPD ➔ Bipolar disorder & Substance
use disorder
− −
3 2.88 2.85–2.90b 14.4 14.3–14.5b 4.90 4.90–4.91b BPD ➔ Depressive disorder &
Substance use disorder
− −
4 14.3 14.1–14.5b 7.15 7.06–7.25b 4.85 4.84–4.86b BPD ➔ Depressive disorder & Anxiety
disorder & Substance use disorder
− −
3 1.71 1.69–1.73b 8.55 8.45–8.65b 4.80 4.79–4.81b BPD ➔ Substance use disorder & Sleep
disorder
− −
4 1.64 1.62–1.66b 8.21 8.11–8.32b 4.87 4.86–4.88b BPD ➔ Depressive disorder & Substance
use disorder & Sleep disorder
− −
4 1.64 1.62–1.66b 8.21 8.11–8.32b 4.87 4.86–4.88b BPD ➔ Bipolar disorder & Substance use
disorder & Sleep disorder
− −
aCI confidence interval; bStatistical significance
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conditions [42], clinicians caring for people with per-
sonality disorders must be aware of possible medical
comorbidities associated with such disorders [43]. Fur-
thermore, gender differences in physical comorbidity
profiles were noted in our study. Comorbidities of the
respiratory system, digestive system, genitourinary system,
endocrine, metabolic, and immune system, neoplasm, and
blood and blood-forming system were more prevalent for
female BPD patients than for male BPD patients. Because
BPD is more common in women than in men [3], more
attention should be focused on the evaluation of physical
comorbidities in patients with BPD.
We observed that the risk of depressive disorder, bipo-
lar disorder, anxiety disorder, substance use disorder,
and sleep disorder in BPD patients was higher than that
in non-BPD patients; this finding is consistent with
those of previous studies [3, 16–18]. BPD is commonly
associated with high rates of psychiatric comorbidity. In
urban primary care patients, the majority (91%) of pa-
tients screening positive for BPD satisfied the criteria for
at least one current Diagnostic and Statistical Manual of
Mental Disorders-IV Axis I diagnosis [19]. Zimmerman
et al. reported that people with BPD satisfy the criteria
for an average of 3.0–3.4 current Axis I disorders and
4.2–4.8 lifetime Axis I disorders [16]. In addition, they
revealed that compared with non-BPD patients, BPD pa-
tients more frequently receive diagnoses of mood, anxiety,
substance use, and somatoform disorders [16], which is
highly compatible with the results of our study. Because
psychiatric comorbidities are associated with a heightened
risk of suicidal and nonsuicidal self-injury among people
with BPD [44–46] and have been found to reduce the like-
lihood of achieving remission from BPD [47], determining
potential psychiatric comorbidities in BPD patients is
crucial.
The diagnosis of BPD in patients with mental retard-
ation, where developmental brain abnormality is inher-
ent, has rarely been reported in the literature [48, 49]. In
this study, we found that the risk of mental retardation
in the BPD patients was higher than that in the control
patients. To our knowledge, this is the first report re-
garding this association, and our finding requires further
confirmation.
In the field of psychiatry, several articles have discussed
the comorbidity rates of BPD with “only one” other dis-
ease. However, few have discussed the comorbidity rates
of three or more diseases. We used ARM in our study for
two main reasons. First, ARM enabled us to observe the
associations among three or more diagnoses simultan-
eously. Second, the value of confidence is arithmetically
synonymous with the “comorbidity rate” in epidemiology.
Using ARM, we determined that BPD was highly concur-
rent with “bipolar disorder and anxiety disorder” (43.49%),
“depressive disorder and anxiety disorder” (41.49%),
“bipolar disorder and sleep disorder” (36.30%), “depressive
disorder and sleep disorder” (35.27%), “anxiety disorder
and sleep disorder” (25.34%), “bipolar disorder, anxiety
disorder, and sleep disorder” (confidence 23.63%), “de-
pressive disorder, anxiety disorder, and sleep disorder”
(22.60%), “bipolar disorder and substance use disorder”
(15.07%), “depressive disorder and substance use dis-
order” (14.38%), “depressive disorder, anxiety disorder,
and substance use disorder” (8.2%), “substance use dis-
order and sleep disorder” (7.7%), “depressive disorder,
substance use disorder, and sleep disorder” (7.4%), and
“bipolar disorder, substance use disorder, and sleep dis-
order” (7.2%). According to our results, most patients
with BPD have two or more psychiatric comorbidities.
Clinicians caring for people with BPD must be aware of
this and determine potential psychiatric comorbidities
in detail.
The strength of our study is that the study design in-
cluded an unbiased patient selection process. Because par-
ticipation in the NHI is mandatory and because all
residents of Taiwan can access health care with low copay-
ments, referral bias is low in our study. Furthermore, we
partitioned the collected data into training and testing sets
and found that the discovered association rules were vali-
dated. However, our study has some limitations. First, in-
formation regarding the family history, lifestyle factors,
and environmental factors of those with physical and psy-
chiatric disorders are not included in the NHIRD, all of
which may be associated with the prevalence of comorbid-
ities. Second, in studies entailing the use of the NHIRD,
how diagnostic classification has been conducted, particu-
larly for psychiatric diagnoses, is unclear. Therefore, the
diagnostic accuracy in our study could not be ascertained.
Additional studies with patients diagnosed through struc-
tured interviews or standard diagnostic criteria should be
conducted to investigate the association between comor-
bidities and BPD. Third, the duration of the observational
period in our study might have been insufficient. In
addition, different duration of observational period might
be a confounding variable of our study. Future studies
with longer and different observational periods are thus
required. Fourth, the composition of our study subjects is
different from the composition of general population and
the support and lift of a rule in the case–control matched
population may be different from the support and lift of
the same rule in the entire population. The difference be-
tween our study population and another population of
interest should thus be taken into account when applying
our results in a different context. Finally, the categories of
physical comorbidities in our study might be too broad
and many minor diseases were enrolled which resulted in
high disease prevalence. Further studies with finer disease
categories are required to investigate physical comorbidi-
ties of BPD patients.
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Conclusions
Our population-based retrospective case–control study
revealed that physical comorbidities were more common
in the BPD patients than in the control patients. In
addition, psychiatric comorbidities including depressive
disorder, bipolar disorder, anxiety disorder, sleep disorder,
substance use disorder, and mental retardation were more
common in the BPD patients than in the control patients.
Furthermore, the associations of BPD and two or more co-
morbidities were demonstrated using ARM. Population-
based large prospective studies are required to further
validate our findings.
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